Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Actinogen Medical Limited ( (AU:ACW) ) has provided an announcement.
Actinogen Medical Limited is advancing its XanaMIA phase 2b/3 clinical trial for Alzheimer’s disease, with significant progress in patient recruitment and randomization. The trial, aiming to enroll 220 participants, focuses on those with elevated pTau181 levels to enhance treatment efficacy detection. As part of its commercial readiness initiatives, the company is conducting regulatory meetings, exploring partnerships, scaling manufacturing, and securing intellectual property protection to bolster Xanamem’s market presence. The recent granting of a unique International Nonproprietary Name by the WHO for Xanamem underscores its novel therapeutic approach, enhancing its industry positioning and potential stakeholder benefits.
More about Actinogen Medical Limited
Actinogen Medical Limited operates in the biotechnology industry, focusing on the development of novel treatments for neurological disorders. The company’s primary product is Xanamem, an orally administered molecule that inhibits brain tissue cortisol synthesis, targeting conditions such as Alzheimer’s disease and major depressive disorder. Actinogen is actively preparing for the commercialization of Xanamem, engaging in regulatory, partnering, and manufacturing initiatives to support its market entry.
YTD Price Performance: 0%
Average Trading Volume: 810,100
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $51.08M
Find detailed analytics on ACW stock on TipRanks’ Stock Analysis page.
